Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

3(60%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Detailed Status

Recruiting3

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

recruiting360%

completed240%

Recent Activity

3 active trials

Showing 5 of 5

recruitingphase_2

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

NCT06231381

recruitingphase_2

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

NCT06477536

recruitingphase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT06231381Phase 2

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

Recruiting

NCT06477536Phase 2

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Recruiting

NCT06716151Phase 1

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

Recruiting

NCT05512598Phase 1

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Completed

NCT05064345Phase 1

A Study to Evaluate HB0034 in Healthy Adult Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5